Who are COVID-19 Standard Treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mRNA-1273 Variant-containing Formulation, COVID-19 mRNA vaccine, mRNA-1273, BioNTech - Pfizer COVID-19 vaccine, Casirivimab and Imdevimab Drug Combination, COVID-19 vaccination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/covid-19-standard-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

COVID-19 Standard Treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Standard Treatment (COVID-19 Standard Treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Disease.

phase 2 SARS-CoV-2 spike protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

COVID-19 Standard Treatment (COVID-19 Standard Treatment) — Dermama Bioteknologi Laboratorium. This drug targets the SARS-CoV-2 virus to prevent COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
COVID-19 Standard Treatment TARGET	COVID-19 Standard Treatment	Dermama Bioteknologi Laboratorium	phase 2		SARS-CoV-2 spike protein
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
BioNTech - Pfizer COVID-19 vaccine	BioNTech - Pfizer COVID-19 vaccine	University of Birmingham	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
COVID-19 vaccination	COVID-19 vaccination	University Medical Center Groningen	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COVID-19 Standard Treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/covid-19-standard-treatment. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab